Odense C

• A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple My … Ended
  2023-504571-25-00 3 2020-10-20 Relapsed or Refractory Multiple Myeloma
• Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery Ended
  2024-511171-15-00 3 2020-07-06 Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
• Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC Ended
  2023-507024-24-00 5 2020-05-05 Metastatic hormone sensitive prostate cancer
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w
• Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended
  2023-507669-24-00 5 2019-11-05 Chronic lymphocytic leukemia
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su … Ended
  2022-501971-24-00 5 2019-05-20 Adjuvant treatment of HCC
• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinoma Ended
  2023-508890-10-00 5 2018-12-05 Gastric and gastric esophageal junction (GEJ) adenocarcinoma
• Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) Ended
  2024-515748-22-01 5 2018-12-01 Myocardinal infarction
• KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study Ended
  2024-511714-20-00 4 2018-01-30 Multiple Myeloma
• Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of pr … Ended
  2023-510200-42-00 5 2017-12-06 primary sclerosing cholangitis (PSC)
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 7 Hodgkin lymphoma or non-Hodgkin lymphoma
• CHRONOS - A study to learn about the effects and safety of ODM-111 in participants with long-lasting pain due to osteoarthritis of the knee. Ended
  2024-513553-79-00 4 Chronic Pain due to Ostheoarthritis of the knee
• Subcutaneous Immunoglobulin in De-novo CIDP - SIDEC Ended
  2024-515898-96-01 11 Chronic inflammatory demyelinating polyneuropathy (CIDP)

Showing 433–456 of 457 trials